Julia Harwardt
Overview
Explore the profile of Julia Harwardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lipinski B, Unmuth L, Arras P, Endruszeit R, Becker S, Rodel J, et al.
Protein Sci
. 2025 Feb;
34(3):e70072.
PMID: 39981925
In this work, we have generated bispecific interleukin (IL)-12 surrogate agonists based on camelid-derived single-domain antibodies (sdAbs) targeting the IL-12 receptor (IL-12R) subunits IL-12Rβ1 and IL-12Rβ2. Following immunization and antibody...
2.
Fernandez-Quintero M, Guarnera E, Musil D, Pekar L, Sellmann C, Freire F, et al.
Protein Sci
. 2024 Oct;
33(11):e5176.
PMID: 39422475
The humanization of camelid-derived variable domain heavy chain antibodies (VHHs) poses challenges including immunogenicity, stability, and potential reduction of affinity. Critical to this process are complementarity-determining regions (CDRs), Vernier and...
3.
Pfeifer Serrahima J, Schoenfeld K, Kuhnel I, Harwardt J, Macarron Palacios A, Prufer M, et al.
Front Immunol
. 2024 Sep;
15:1457887.
PMID: 39267747
NKG2D is an activating receptor expressed by natural killer (NK) cells and other cytotoxic lymphocytes that plays a pivotal role in the elimination of neoplastic cells through recognition of different...
4.
Schoenfeld K, Habermann J, Wendel P, Harwardt J, Ullrich E, Kolmar H
Mol Ther Oncol
. 2024 Aug;
32(3):200850.
PMID: 39176070
T cell-derived cancers are hallmarked by heterogeneity, aggressiveness, and poor clinical outcomes. Available targeted therapies are severely limited due to a lack of target antigens that allow discrimination of malignant...
5.
Harwardt J, Geyer F, Schoenfeld K, Baumstark D, Molkenthin V, Kolmar H
Antibodies (Basel)
. 2024 May;
13(2).
PMID: 38804304
The optimization of the affinity of monoclonal antibodies is crucial for the development of drug candidates, as it can impact the efficacy of the drug and, thus, the dose and...
6.
Ulitzka M, Harwardt J, Lipinski B, Tran H, Hock B, Kolmar H
Molecules
. 2024 Mar;
29(5).
PMID: 38474651
Valued for their ability to rapidly kill multiple tumor cells in succession as well as their favorable safety profile, NK cells are of increasing interest in the field of immunotherapy....
7.
Schoenfeld K, Harwardt J, Kolmar H
Biol Chem
. 2024 Feb;
405(7-8):443-459.
PMID: 38297991
Antibody-based therapies are revolutionizing cancer treatment and experience a steady increase from preclinical and clinical pipelines to market share. While the clinical success of monoclonal antibodies is frequently limited by...
8.
Schoenfeld K, Harwardt J, Habermann J, Elter A, Kolmar H
Front Immunol
. 2023 Oct;
14:1258700.
PMID: 37841262
Cancerous B cells are almost indistinguishable from their non-malignant counterparts regarding their surface antigen expression. Accordingly, the challenge to be faced consists in elimination of the malignant B cell population...
9.
Harwardt J, Carrara S, Bogen J, Schoenfeld K, Grzeschik J, Hock B, et al.
Front Immunol
. 2023 Apr;
14:1170042.
PMID: 37081888
To construct a trispecific IgG-like antibody at least three different binding moieties need to be combined, which results in a complex architecture and challenging production of these molecules. Here we...
10.
Carrara S, Harwardt J, Grzeschik J, Hock B, Kolmar H
Front Immunol
. 2022 Nov;
13:1051875.
PMID: 36439165
Harnessing the innate power of T cells for therapeutic benefit has seen many shortcomings due to cytotoxicity in the past, but still remains a very attractive mechanism of action for...